Primary indication:
Optic neuritis related to multiple sclerosis
•ACR101 is being developed for optic neuritis associated with multiple sclerosis (MS) to reduce demyelinating inflammation of the optic nerve
•Unmet medical need: no treatment available except for corticosteroids
•Number of patients: US annual incidence estimated at 6.4 per 100’000, UK prevalence about 114 case for 100’000
•Efficacy demonstrated in optic neuritis associated with MS would support development in chronic progressive MS
Multiple Sclerosis – Progressive Forms – RARE DISEASE
•Myelin continually degrades leading to axon degeneration and neuronal death
•Neurodegeneration is responsible for chronic disability and MS progression
•Current MS treatments are based on immunosuppression with little action, if any, on neuroprotection: progressive forms are hardly treated
